Isolation of potent SARS-CoV-2 neutralizing antibodies and protection from disease in a small animal model

Rogers, Thomas F., Zhao, Fangzhu, Huang, Deli, Beutler, Nathan, Burns, Alison, He, Wan-ting, Limbo, Oliver, Smith, Chloe +26 more·2020·Science
DOI 10.1126/science.abc7520

Cited by (1,034)

Items 801–900 of 1,034

  1. SARS-CoV-2 Spike evolution influences GBP and IFITM sensitivity
    Dejan Mesner, Ann-Kathrin Reuschl, M. Whelan, Taylor Bronzovich, Tafhima Haider, Lucy G. Thorne, G. Towers, Clare Jolly · 2022 · bioRxiv
  2. An intranasal nanoparticle STING agonist has broad protective immunity against respiratory viruses and variants
    Ankita Leekha, A. Saeedi, Monish Kumar, Samiur Rahman Sefat, M. Paniagua, Mohsen Fathi, Rohan Kulkarni, Sujit Biswas, D. Tsitoura, Xinli Liu et al. · 2022 · bioRxiv
  3. Chemically Modified Bacterial Sacculi as a Vaccine Microparticle Scaffold
    P. Weidenbacher, F. Rodriguez-Rivera, M. Sanyal, J. A. Visser, J. Do, C. Bertozzi, Peter S. Kim · 2022 · ACS Chemical Biology
  4. Mosaic RBD nanoparticles protect against multiple sarbecovirus challenges in animal models
    Alexander A. Cohen, N. van Doremalen, Allison J. Greaney, H. Andersen, Ankur Sharma, Tyler N. Starr, J. Keeffe, Chen-Hua Fan, Jonathan E. Schulz, Priyanthi N. P. Gnanapragasam et al. · 2022 · bioRxiv
  5. Thinking Outside the Box: Utilizing Nontraditional Animal Models for COVID-19 Research
    Sachithra Gunasekara, Miruthula Tamil Selvan, Craig A. Miller, Jennifer M. Rudd · 2022 · International Journal of Translational Medicine
  6. Exploring Rapid and Effective Screening Methods for Anti-SARS-CoV-2 Neutralizing Antibodies in COVID-19 Convalescent Patients and Longitudinal Vaccinated Populations
    Caiqin Hu, Dan Li, Zhanmou Liu, Li Ren, Junwei Su, Meiling Zhu, Yi Feng, Zheng Wang, Qiang Liu, Biao Zhu et al. · 2022 · Pathogens
  7. Two doses of mRNA vaccine elicit cross-neutralizing memory B-cells against SARS-CoV-2 Omicron variant
    Ryutaro Kotaki, Yu Adachi, Saya Moriyama, T. Onodera, S. Fukushi, Takaki Nagakura, K. Tonouchi, K. Terahara, Lin Sun, Tomohiro Takano et al. · 2021 · bioRxiv
  8. Anti-SARS-CoV-2 IgG and IgA antibodies in COVID-19 convalescent plasma do not facilitate antibody-dependent enhance of viral infection.
    Natasha M. Clark, S. Janaka, William Hartman, S. Stramer, E. Goodhue, J. Weiss, David T. Evans, J. Connor · 2021 · bioRxiv
  9. Altered interaction between RBD and ACE2 receptor contributes towards the increased transmissibility of SARS CoV-2 delta, kappa, beta, and gamma strains with RBD double mutations
    S. Sinha, Benjamin Tam, San-Ming Wang · 2021
  10. Tetravalent SARS-CoV-2 Neutralizing Antibodies Show Enhanced Potency and Resistance to Escape Mutations
    Shane Miersch, Zhijie Li, Reza Saberianfar, Mart Ustav, James Brett Case, Levi L. Blazer, Chao Chen, W. Ye, A. Pavlenco, Maryna Gorelik et al. · 2021 · Journal of Molecular Biology
  11. A cGAMP-containing hydrogel for prolonged SARS-CoV-2 RBD subunit vaccine exposure induces a broad and potent humoral response
    V. Böhnert, Emily C. Gale, L. Lahey, Jerry Yan, Abigail E. Powell, Ben S. Ou, J. Carozza, Ling-Yin Li, E. Appel · 2021 · bioRxiv
  12. The COVID-19 Treatment Landscape: A South African Perspective on a Race Against Time
    C. Hendricks, C. Herd, M. Nel, G. Tintinger, M. Pepper · 2021 · Frontiers in Medicine
  13. Single-cell sequencing of plasma cells from COVID-19 patients reveals highly expanded clonal lineages produce specific and neutralizing antibodies to SARS-CoV-2
    Roy A. Ehling, Cédric R. Weber, Derek M. Mason, Simon Friedensohn, Bastian Wagner, Florian Bieberich, Edo Kapetanovic, Rodrigo Vazquez-Lombardi, Raphaël B. Di Roberto, Kai-Lin Hong et al. · 2021 · bioRxiv
  14. Early therapy with remdesivir and antibody combinations improves COVID-19 disease in mice
    David R. Martinez, A. Schaefer, S. Leist, K. Gully, Joy Y. Feng, Elaine Bunyan, D. Porter, T. Cihlář, S. Montgomery, R. Baric et al. · 2021 · bioRxiv
  15. Next generation vaccine platform: polymersomes as stable nanocarriers for a highly immunogenic and durable SARS-CoV-2 spike protein subunit vaccine
    J. Lam, Amita Khan, T. A. Cornell, R. Dress, Teck Wan Chia, Wen Wang William Yeow, N. K. Mohd-Ismail, Shrinivas Venkatraman, Kim Tien Ng, Yee-Joo Tan et al. · 2021 · bioRxiv
  16. Paired heavy and light chain signatures contribute to potent SARS-CoV-2 neutralization in public antibody responses
    B. B. Banach, G. Cerutti, A. Fahad, Chen-Hsiang Shen, M. D. de Souza, P. Katsamba, Y. Tsybovsky, Pengfei Wang, M. Nair, Yao-Xing Huang et al. · 2020 · bioRxiv
  17. Cross-reactive coronavirus antibodies with diverse epitope specificities and extra-neutralization functions
    Andrea R. Shiakolas, Kevin J. Kramer, D. Wrapp, S. Richardson, A. Schäfer, Steven J. Wall, Nian-Shuang Wang, Katarzyna Janowska, Kelsey A. Pilewski, R. Venkat et al. · 2020 · bioRxiv
  18. Neutralizing SARS-CoV-2
    E. Poeschla · 2020 · eLife
  19. Therapeutic and Vaccine Options for COVID-19: Status after Six Months of the Disease Outbreak
    Dawid Maciorowski, C. Ogaugwu, S. R. Durvasula, R. Durvasula, A. Kunamneni · 2020 · SLAS discovery : advancing life sciences R & D
  20. Asynchronous actions of immune responses in COVID-19 patients
    Yu-Fang Shi, Guo-Qiang Zhou, Qing Li · 2020 · Signal Transduction and Targeted Therapy
  21. Robust antibody and T cell responses tracked longitudinally in patients with long COVID
    M. Metaxaki, R. Ram, Marianne Perera, Mark Wills, B. Krishna, N. Sithole · 2025 · Journal of General Virology
  22. Comparison of Three Commercial ELISA Kits for Detection of Antibodies Against SARS-CoV-2 in Serum Samples from Different Animal Species
    Leira Fernández-Bastit, S. Marfil, Edwards Pradenas, Julian Blanco, J. Vergara-Alert, J. Segalés · 2025 · Viruses
  23. Optimization of Cellular Transduction by the HIV-Based Pseudovirus Platform with Pan-Coronavirus Spike Proteins
    Syamala Rani Thimmiraju, María José Villar, Jason T. Kimata, Ulrich Strych, María Elena Bottazzi, Peter Jay Hotez, Jeroen B. K. Pollet · 2024 · Viruses
  24. Rapid generation of human recombinant monoclonal antibodies from antibody-secreting cells using ferrofluid-based technology
    Veronica Strazza, Marco Rossi, Andrea Avati, Giusy Tiseo, Marco Falcone, Maria Grazia Cusi, Francesco Menichetti, Paola Ricciardi‐Castagnoli, Cristina Tinti, Piero Pileri · 2024 · Frontiers in Immunology
  25. Tracking the immune response profiles elicited by the BNT162b2 vaccine in COVID-19 unexperienced and experienced individuals
    Eugenia Galeota, Valeria Bevilacqua, Andrea Gobbini, Paola Gruarin, Mauro Bombaci, Elisa Pesce, Andrea Favalli, Andrea Lombardi, Francesca Vincenti, Jessica Ongaro et al. · 2024 · Clinical Immunology
  26. To be remembered: B cell memory response against SARS‐CoV ‐2 and its variants in vaccinated and unvaccinated individuals
    Nafees Ahmed, Atharv Athavale, Ankita Harishchandra Tripathi, Adarsh Subramaniam, Santosh Kumar Upadhyay, Anil Kumar Pandey, Ramesh Chandra Rai, Amit Awasthi · 2023 · Scandinavian Journal of Immunology
  27. Cryptic-site-specific antibodies to the SARS-CoV-2 receptor binding domain can retain functional binding affinity to spike variants
    Kan Li, Richard H. C. Huntwork, G. Horn, Milite Abraha, K. Hastie, Hao-Yang Li, Vamseedhar Rayaprolu, Eduardo Olmedillas, E. Feeney, Ken Cronin et al. · 2023 · Journal of Virology
  28. Dendritic Cell‐Mediated Cross‐Priming by a Bispecific Neutralizing Antibody Boosts Cytotoxic T Cell Responses and Protects Mice against SARS‐CoV‐2
    Rodrigo Lázaro‐Gorines, Patricia Pérez, Ignacio Heras‐Murillo, Irene Adán‐Barrientos, Guillermo Albericio, David Astorgano, Sara Flores, Joanna Luczkowiak, Nuria Labiod, Seandean L. Harwood et al. · 2023 · Advanced Science
  29. SARS‐CoV‐2 neutralising antibody therapies: Recent advances and future challenges
    Mingtao Liu, Zhiman Liang, Zhangkai Jason Cheng, Li Liu, Qiwen Liu, Yiyin Mai, Hui‐Huang Chen, Baoying Lei, Shangwei Yu, Huihui Chen et al. · 2023 · Reviews in Medical Virology
  30. CD62L expression marks SARS-CoV-2 memory B cell subset with preference for neutralizing epitopes
    Taishi Onodera, Nicolas Sax, Takashi Sato, Yu Adachi, Ryutaro Kotaki, Takeshi Inoue, Ryo Shinnakasu, Takayuki Nakagawa, Shuetsu Fukushi, Tommy W. Terooatea et al. · 2023 · Science Advances
  31. Impaired potency of neutralizing antibodies against cell–cell fusion mediated by SARS-CoV-2
    Qian Wang, Andre Yanchen Yeh, Yi-Cheng Guo, H. Mohri, J. Yu, D. Ho, Li-Hong Liu · 2023 · bioRxiv
  32. Formulation development and comparability studies with an aluminum-salt adjuvanted SARS-CoV-2 spike ferritin nanoparticle vaccine antigen produced from two different cell lines
    Ozan S. Kumru, M. Sanyal, N. Friedland, J. Hickey, Richa Joshi, P. Weidenbacher, Jonathan Do, Ya-Chen Cheng, Peter S. Kim, S. Joshi et al. · 2023 · bioRxiv
  33. Longitudinal Characterization of Phagocytic and Neutralization Functions of Anti-Spike Antibodies in Plasma of Patients after Severe Acute Respiratory Syndrome Coronavirus 2 Infection
    A. Adhikari, Arunasingam Abayasingam, C. Rodrigo, David Agapiou, E. Pandžić, Nicholas A. Brasher, B. S. Fernando, Elizabeth Keoshkerian, Hui Li, Ha Na Kim et al. · 2022 · Journal of Immunology
  34. Differential persistence of neutralizing antibody against SARS-CoV-2 in post immunized Bangladeshi population
    Dipa Rani Roy, Md. Mosfequr Rahman, Arnaba Saha Chaity, Md Abu Reza, Ariful Haque · 2022 · Scientific Reports
  35. The DNA glycosylase NEIL2 plays a vital role in combating SARS-CoV-2 infection
    T. Hazra, N. Tapryal, Anirban Chakraborty, Kempaiah Rayavara, M. Wakamiya, A. Islam, L. Pan, Jason C. Hsu, Vivian Tat, Junki Maruyama et al. · 2022 · Research Square
  36. P681 mutations within the polybasic motif of spike dictate fusogenicity and syncytia formation of SARS CoV-2 variants
    A. Kuzmina, N. Atari, A. Ottolenghi, D. Korovin, Ido Cohen lass, B. Rosental, Elli Rosenberg, M. Mandelboim, R. Taube · 2022 · bioRxiv
  37. SARS-CoV-2 evolution and immune escape in immunocompromised patients treated with exogenous antibodies
    E. Scherer, A. Babiker, M. Adelman, B. Allman, A. Key, J. Kleinhenz, R. M. Langsjoen, Phuong-Vi Nguyen, I. Onyechi, J. D. Sherman et al. · 2022 · medRxiv
  38. Formation and Expansion of Memory B Cells against Coronavirus in Acutely Infected COVID-19 Individuals
    A. Embong, Phuong Nguyen-Contant, Jiong Wang, Preshetha Kanagaiah, F. Chaves, T. Fitzgerald, Qian Zhou, G. Kosoy, A. Branche, Benjamin L. Miller et al. · 2022 · Pathogens
  39. Neutralizing monoclonal antibodies against highly pathogenic coronaviruses
    Rong Xiang, Yang Wang, Lili Wang, Xiaoqian Deng, Shanshan Huo, Shibo Jiang, Fei Yu · 2021 · Current Opinion in Virology
  40. Application of SARS-CoV-2 Serology to Address Public Health Priorities
    Amy C Sherman, Teresa Smith, Yerun Zhu, Kaitlin R. Taibl, Jessica R Howard-Anderson, Taylor Landay, Nora Pisanic, Jennifer Kleinhenz, Trevor W. Simon, Daniel Espinoza et al. · 2021 · Frontiers in Public Health
  41. Epitope Analysis of Anti-SARS-CoV-2 Neutralizing Antibodies
    Jun-biao Xue, Sheng-Ce Tao · 2021 · Current Medical Science
  42. SARS-CoV-2–Reactive Mucosal B Cells in the Upper Respiratory Tract of Uninfected Individuals
    Yanling Liu, P. Budylowski, Shilan Dong, Zhi-Jie Li, S. Goroshko, Leslie Y. T. Leung, E. Grunebaum, P. Campisi, E. Propst, N. Wolter et al. · 2021 · Journal of Immunology
  43. Point Mutations in SARS-CoV-2 Variants Induce Long-Range Dynamical Perturbations in Neutralizing Antibodies
    Dhiman Ray, Riley Quijano, I. Andricioaei · 2021 · bioRxiv
  44. Anti-CD38 therapy impairs SARS-CoV-2 vaccine response in multiple myeloma patients
    S. Henriquez, Jeremie Zerbit, T. Bruel, A. Ouedrani, D. Planas, P. Deschamps, I. Staropoli, J. Hadjadj, B. Varet, F. Suarez et al. · 2021 · medRxiv
  45. Progression and Resolution of SARS-CoV-2 Infection in Golden Syrian Hamsters
    Kathleen R. Mulka, S. Beck, Clarisse V. Solis, Andrew L. Johanson, S. Queen, Megan E. McCarron, M. Richardson, Rui-Feng Zhou, Paula Marinho, Anne Jedlicka et al. · 2021 · bioRxiv
  46. A Comprehensive Review of Possible Immune Responses against Novel SARS-CoV-2 Coronavirus: Vaccines Strategies and Challenges
    Asif Shahriar, Mukhametzianova Ar, H. Ahmed, N. Rahman, Khatun Mc, Джусипбекова Б. А. · 2021 · Austin Journal of Microbiology
  47. Modelling the population-level protection conferred by COVID-19 vaccination
    Pranesh Padmanabhan, Rajat Desikan, Narendra M. Dixit · 2021 · medRxiv
  48. Sex disparities and neutralizing antibody durability to SARS-CoV-2 infection in convalescent individuals
    A. Markmann, Natasa Giallourou, D. R. Bhowmik, Y. Hou, Aaron Lerner, David R. Martinez, L. Premkumar, H. Root, D. van Duin, S. Napravnik et al. · 2021 · medRxiv
  49. Deep mining of early antibody response in COVID-19 patients yields potent neutralisers and reveals high level of convergence
    Georgia Bullen, J. Galson, Pedro Villar, Lien Moreels, Line Ledsgaard, G. Mattiuzzo, G. Hall, E. Bentley, Edward W. Masters, David M Tang et al. · 2020 · bioRxiv
  50. In vitro measurements of protein–protein interactions show that antibody affinity governs the inhibition of SARS-CoV-2 spike/ACE2 binding in convalescent serum
    S. Fiedler, Monika A. Piziorska, Viola Denninger, A. Morgunov, A. Ilsley, Anisa Y. Malik, Matthias M. Schneider, S. Devenish, G. Meisl, A. Aguzzi et al. · 2020 · bioRxiv
  51. IgG‐Bridging–Seeded Synergistic Aggregation of SARS‐CoV‐2 Spikes Underlies Potent Neutralization by a Low‐Affinity Antibody
    Nian-Nian Lv, Peng Chen, X. Dai, Hu Xu, Zi-Heng Li, Zelin Shan, Jin-Qian Li, Feng-Lin Guo, Yuan-Fang Chen, Jia-Yi Li et al. · 2025 · bioRxiv
  52. Development of a Novel Homogeneous Liposome-Based One-Step Assay for SARS-CoV‑2 Antibody Detection in Human Serum Based on Fluorescent Liposomes and Complement Activity
    Christina Reiner, Kilian Hoecherl, Sebastian Einhauser, Simon Streif, Clemens Spitzenberg, Johannes Konrad, Patrick Neckermann, M. Breunig, Diana Pauly, Ralf Wagner et al. · 2025 · Analytical Chemistry
  53. A HiBiT-tagged pseudovirus-like particle platform for safe, rapid quantification of virus neutralization and antibody-dependent enhancement
    Jonathan K. Mitchell, Vincent Mastrodomenico, Jim Hartnett, William J. Heelan, Denise K. Garvin, Mei Cong, Jamison J. Grailer · 2025 · Journal of Virology
  54. Longitudinal Innate and Heterologous Adaptive Immune Responses to SARS‐CoV‐2 JN.1 in Transplant Recipients With Prior Omicron Infection: Limited Neutralization but Robust CD4+ T‐Cell Activity
    V. H. Ferreira, Brandon Keith, F. Mavandadnejad, A. Ferro, Sara Marocco, G. Amidpour, Alexandra Kurtesi, Fredo Qi, A. Gingras, Victoria G. Hall et al. · 2025 · Transplant Infectious Disease
  55. Review on the current status of Syrian hamsters as an animal model for COVID-19 transmission, pathogenesis, treatment and vaccine research
    Biruh Mebratu Belay, A. T. Gessese, M. Kinde, G. G. Dagnaw · 2025 · All Life
  56. Vitamin D as an Adjuvant Immune Enhancer to SARS-Cov-2 Vaccine
    Azza Salamony, Maha Abdelsalam, Nancy Elguindy, W. Roshdy, Amr Youssef, Yara I Shamikh · 2025 · Current Microbiology
  57. Cellular Nanoparticles Treat Coronavirus Infection in Vivo
    Yi-Yan Yu, Daniela Silva-Ayala, Zhi-Dong Zhou, Yifei Peng, Ronnie H. Fang, Wei-Wei Gao, Anthony Griffiths, Liang-Fang Zhang · 2024 · Nano letters (Print)
  58. Research topic displacement and the lack of interdisciplinarity: lessons from the scientific response to COVID-19
    Eva Seidlmayer, Tetyana Melnychuk, Lukas Galke Poech, Lisa Kühnel, Klaus Tochtermann, Carsten Schultz, K. Förstner · 2024 · Scientometrics
  59. No evidence for enhanced disease with human polyclonal SARS-CoV-2 antibody in the ferret model
    Douglas S. Reed, Anita K. McElroy, Dominique J. Barbeau, Cynthia M. McMillen, N. L. Tilston-Lunel, Sham Nambulli, Emily Cottle, Theron C. Gilliland, Hasala Rannulu, Jeneveve D. Lundy et al. · 2024 · PLoS ONE
  60. Development of a quantitative ELISA for SARS-CoV-2 vaccine candidate, NDV-HXP-S, with CpG 1018® adjuvant
    Marcus Estrada, Chang-Cheng Zhu, Anan Bzami, Jessica A. White, M. Lal · 2024 · Human Vaccines & Immunotherapeutics
  61. Pediococcus pentosaceus MIANGUAN Enhances the Immune Response to Vaccination in Mice
    Yulu Chen, Zhijie Cao, Simin Lu, Zhihuan Wang, Caiyun Ma, Gui Zhang, Meng-Shan Chen, Jing Yang, Zhi-Hong Ren, Jian-Guo Xu · 2024 · Probiotics and Antimicrobial Proteins
  62. The Abundant Distribution and Duplication of SARS-CoV-2 in the Cerebrum and Lungs Promote a High Mortality Rate in Transgenic hACE2-C57 Mice
    Heng Li, Xin Zhao, Shasha Peng, Ying-Yan Li, Jing Li, Hui-Wen Zheng, Yi-Fan Zhang, Yu-Rong Zhao, Yuan Tian, Jin-Ling Yang et al. · 2024 · International Journal of Molecular Sciences
  63. Site-directed neutralizing antibodies targeting structural sites on SARS-CoV-2 spike protein
    Xiaofeng Li, Liudmila Kulakova, Kezzia S. Jones, E. Toth, M. Mitchell, Qiana Mendez, Michael P. Weiner, T. Fuerst · 2023 · New Biotechnology
  64. A fine-tuned yeast surface-display/secretion platform enables the rapid discovery of neutralizing antibodies against Clostridioides difficile toxins
    Yinghui Sun, Yong-Rong Zhang, Hua Yu, Ashley Saint Fleur, Di Yu, Zhi-Yong Yang, Han-Ping Feng · 2023 · Microbial Cell Factories
  65. Decreased efficacy of a COVID-19 vaccine due to mutations present in early SARS-CoV-2 variants of concern
    P. Weidenbacher, N. Friedland, M. Sanyal, M. Morris, Jonathan Do, C. Hanson, Peter S. Kim · 2023 · bioRxiv
  66. Impaired immunogenicity after vaccination for SARS-CoV-2 in patients with gastrointestinal cancer: does tumor entity matter?
    Malte B. Monin, Jens Gabriel Gorny, Moritz Berger, Leona I. Baier, Taotao Zhou, Robert Mahn, Farsaneh Sadeghlar, Christian Möhring, Christoph Boesecke, Kahtrin van Bremen et al. · 2023 · Journal of Gastrointestinal Oncology
  67. Development of a Single-Chain Fragment Variable that Binds to the SARS-CoV-2 Spike Protein Produced by Genetically Modified Lactic Acid Bacteria
    Suzuka Oshima, Na-Mai Fu, Takashi Sato, T. Shimosato · 2023 · Molecular Biotechnology
  68. Exploring the Potential of Broadly Neutralizing Antibodies for Treating SARS-CoV-2 Variants of Global Concern in 2023: A Comprehensive Clinical Review
    S. D. Gutlapalli, Vijay Durga Pradeep Ganipineni, Sumanth Danda, Daniel Fabian, Ikpechukwu J Okorie, Jananthan Paramsothy, Tharunjan Kailayanathan, Rushaniya Umyarova, Cinthya Aviles, S. Garlapati et al. · 2023 · Cureus
  69. Development of neutralizing antibodies against SARS-CoV-2, using a high-throughput single-B-cell cloning method
    Yang Dou, Ke Xu, Yong‐Qiang Deng, Zijing Jia, Jun Lan, Xiaoyu Xu, Guorui Zhang, Tian-Shu Cao, Pan Liu, Xiangxi Wang et al. · 2023 · Antibody Therapeutics
  70. Immunotherapeutic and immunomodulatory potentials of Antigen-Antibody complex vaccines
    D. Naz, S. Ur Rahman, Muhammad Aamir Aslam, Faqir Muhammad · 2022 · Medical Hypotheses
  71. Site of vulnerability on SARS-CoV-2 spike induces broadly protective antibody to antigenically distinct omicron SARS-CoV-2 subvariants
    S. Changrob, P. Halfmann, Hejun Liu, J. Torres, J. McGrath, G. Ozorowski, Lei Li, M. Kuroda, Tadashi Maemura, Min Huang et al. · 2022 · bioRxiv
  72. Ancestral SARS-CoV-2-Driven Antibody Repertoire Diversity in an Unvaccinated Individual Correlates with Expanded Neutralization Breadth
    Suprit Deshpande, M. Y. Ansari, Jyoti Sutar, Payel Das, Nitin K Hingankar, S. Mukherjee, Priyanka Jayal, Savita Singh, A. Anantharaj, Janmejay Singh et al. · 2022 · bioRxiv
  73. Exploiting V-Gene Bias for Rapid, High-Throughput Monoclonal Antibody Isolation from Horses
    C. K. Wibmer, Poppy Mashilo · 2022 · Viruses
  74. Prolonged Protective Immunity Induced by Mild SARS-CoV-2 Infection of K18-hACE2 Mice
    Liat Bar‐On, Moshe Aftalion, Efi Makdasi, David Gur, Ron Alcalay, Hila Cohen, Adi Beth-Din, Ronit Rosenfeld, Hagit Achdout, Erez Bar‐Haim et al. · 2022 · Vaccines
  75. The efficacy, safety and immunogenicity Nanocovax: results of a randomized, double-blind, placebo-controlled Phase 3 trial.
    T. Nguyen, Quyet Do, L. T. Phan, A. Dang, H. Khong, D. Dinh, Luong van Hoang, T. V. Nguyen, H. Pham, Men Van Chu et al. · 2022 · medRxiv
  76. Next-Generation Molecular Discovery: From Bottom-Up In Vivo and In Vitro Approaches to In Silico Top-Down Approaches for Therapeutics Neogenesis
    Sophie E. Kenny, Fiach Antaw, Warwick J. Locke, Christopher B. Howard, Darren J. Korbie, Matt Trau · 2022 · Life
  77. Prior SARS-CoV2 infection in vaccinated solid organ transplant recipients induces potent neutralization responses against variants, including Omicron
    A. Choudhary, M. Lerman, David Calianese, Salman Khan, J. Hunt, A. Nikaein, W. Honnen, D. Jaijyan, E. Kalu, Abraham Pinter · 2022 · medRxiv
  78. Biologic correlates of beneficial convalescent plasma therapy in a COVID-19 patient reveal disease resolution mechanisms
    N. Bruiners, Valentina Guerrini, Rahul Ukey, Ryan Dikdan, Jason H. Yang, P. Mishra, Alberta Onyuka, D. Handler, Joshua A. Vieth, Mary Carayannopulos et al. · 2022 · medRxiv
  79. A new testing platform using fingerstick blood for quantitative antibody response evaluation after SARS-CoV-2 vaccination
    Jin-Wei Du, Da-Yu Zhang, J. Pathakamuri, D. Kuebler, Yezhou Yang, Yulia Loginova, E. Chu, R. Madej, J. Neves, B. Singer et al. · 2021 · Emerging Microbes and Infections
  80. Broad anti-SARS-CoV-2 antibody immunity induced by heterologous ChAdOx1/mRNA-1273 prime-boost vaccination
    C. I. Kaku, E. Champney, J. Normark, C. E. Johnson, C. Ahlm, M. Sakharkar, M. Ackerman, M. Forsell, L. Walker · 2021 · medRxiv
  81. A Bacterial Cell-Based Assay To Study SARS-CoV-2 Protein-Protein Interactions
    B. L. Springstein, P. Deighan, G. Grabe, A. Hochschild · 2021 · mBio
  82. Antibody screening at reduced pH enables preferential selection of potently neutralizing antibodies targeting SARS‐CoV ‐2
    Bharat Madan, Eswar R. Reddem, Pengfei Wang, Ryan G. Casner, Manoj S. Nair, Yaoxing Huang, Ahmed S. Fahad, Matheus Oliveira de Souza, Bailey B. Banach, Sheila N. López Acevedo et al. · 2021 · AIChE Journal
  83. Targeted isolation of panels of diverse human protective broadly neutralizing antibodies against SARS-like viruses
    Wan-ting He, Rami Musharrafieh, G. Song, K. Dueker, Long-Ping V. Tse, David R. Martinez, A. Schäfer, Sean Callaghan, Peter Yong, N. Beutler et al. · 2021 · bioRxiv
  84. A Rapid Saliva Test for Monitoring Immune Protection against SARS -CoV-2 and its Variants
    Victoria S. A. Momyer, Samantha Dixon, Q. John Liu, Brian Wee, Tiffany Chen, A. E. Petropoulos, L. Jessica Sang · 2021 · medRxiv
  85. Identification of Human SARS-CoV-2 Monoclonal Antibodies from Convalescent Patients Using EBV Immortalization
    Rut Valgardsdottir, Irene Cattaneo, Gavino Napolitano, Annibale Raglio, Orietta Spinelli, Silvia Salmoiraghi, Concetta Castilletti, Daniele Lapa, Maria Rosaria Capobianchi, Claudio Farina et al. · 2021 · Antibodies
  86. Efficient discovery of potently neutralizing SARS-CoV-2 antibodies using LIBRA-seq with ligand blocking
    Andrea R. Shiakolas, N. Johnson, Kevin J. Kramer, Naveenchandra Suryadevara, D. Wrapp, S. Periasamy, Kelsey A. Pilewski, Nagarajan Raju, Rachel S. Nargi, Rachel E. Sutton et al. · 2021 · bioRxiv
  87. One dose of COVID-19 nanoparticle vaccine REVC-128 provides protection against SARS-CoV-2 challenge at two weeks post immunization
    Maggie Gu, J. Torres, J. Greenhouse, Shannon E. Wallace, Chi-I Chiang, A. Jackson, Maciel Porto, S. Kar, Yu-Xing Li, A. Ward et al. · 2021 · bioRxiv
  88. Durability of Viral Neutralization in Asymptomatic Coronavirus Disease 2019 for at Least 60 Days
    Amanda Haymond, Abdulla A Damluji, Aarthi Narayanan, Claudius Mueller, A. Reeder, Farhang Alem, G. Maxwell, E. Petricoin, L. Liotta, C. Defilippi · 2021 · Journal of Infectious Diseases
  89. Potent in vitro Neutralization of SARS-CoV-2 by Hetero-bivalent Alpaca Nanobodies Targeting the Spike Receptor-Binding Domain
    Huan Ma, Weihong Zeng, Xiang-Zhi Meng, Xiaoxue Huang, Yunru Yang, Dan Zhao, Peigen Zhou, Xiao-Fang Wang, Chang-Cheng Zhao, Yong-Jun Sun et al. · 2021 · bioRxiv
  90. Affinity maturation and light-chain-mediated paratope diversification anticipates viral evolution
    John G Dingus, Duck Kyun Yoo, Sachin Kumar, Yajuan Wang, Md. Golam Kibria, Shahab Saghaei, Zahra Allahyari, Jessica W. Chen, Natalie Caputo, Jason Hwang et al. · 2025 · Cell Reports
  91. Enhanced Sampling Reveals Metastable Conformations Driving K417N-Mediated Class I Antibody Escape
    Xu Pan, Takashi Tadokoro, Taishi Onodera, Shunsuke Kita, Yoshimasa Takahashi, Katsumi Maenaka, Hisham M. Dokainish · 2025 · Journal of Chemical Information and Modeling
  92. Mucosal Vaccination Against SARS-CoV-2 Using Human Probiotic Bacillus subtilis Spores as an Adjuvant Induces Potent Systemic and Mucosal Immunity
    Raul Ramos Pupo, Laura M. Reyes Diaz, G. M. Suarez Formigo, Yusnaby Borrego Gonzalez, Miriam Lastre Gonzalez, Danay Saavedra-Hernández, Tania Crombet Ramos, Belinda Sánchez-Ramírez, Roberto Grau, Niels Hellings et al. · 2025 · Vaccines
  93. A distinctive IGHV3-66 SARS-CoV-2 neutralizing antibody elicited by primary infection with an Omicron variant
    Qing Fan, Congcong Liu, Huimin Guo, Shilong Tang, Haiyan Wang, Bing Zhou, Yuehong Sun, Miao Wang, Xiangyang Ge, Lei Liu et al. · 2025 · Structure
  94. Passive infusion of an S2-Stem broadly neutralizing antibody protects against SARS-CoV-2 infection and lower airway inflammation in rhesus macaques
    Steven E. Bosinger, Christopher T Edwards, Kirti A. Karunakaran, Elijah Garcia, Nathan Beutler, Matthew Gagné, Nadia Golden, Hadj Aoued, Kathryn Pellegrini, Matthew R. Burnett et al. · 2025 · PLoS Pathogens
  95. Comparative assessment of a COVID-19 vaccine after technology transfer to Iran from critical quality attributes to clinical and immunogenicity aspects
    D. Doroud, Mona Sadat Larijani, Alireza Biglari, Fatemeh Ashrafian, Talieh Sabouni, Sana Eybpoosh, V. Verez-Bencomo, Y. Valdés-Balbín, D. García-Rivera, Yaneli Herrera-Rojas et al. · 2024 · Scientific Reports
  96. Quantitating SARS-CoV-2 neutralizing antibodies from human dried blood spots
    Katherine Berman, Greta Van Slyke, Hayley Novak, Jean M. Rock, Rachel Bievenue, Amanda K. Damjanovic, Kate L. DeRosa, Gianna Mirabile, K. Phipps, J. Machowski et al. · 2024 · Microbiology spectrum
  97. Identification of an IGHV3-53-Encoded RBD-Targeting Cross-Neutralizing Antibody from an Early COVID-19 Convalescent
    Yuanyuan Hu, Caiqin Hu, Shuo Wang, Li Ren, Yanling Hao, Zheng Wang, Ying Liu, Junwei Su, Biao Zhu, Dan Li et al. · 2024 · Pathogens
  98. Cell-based passive immunization for protection against SARS-CoV-2 infection
    Evan Sawula, Shane Miersch, Eric D. Jong, Chengjin Li, Fang-Yu Chou, Jean Kit Tang, Reza Saberianfar, Jeffrey S. Harding, Sachdev S. Sidhu, András Nagy · 2023 · Stem Cell Research & Therapy
  99. The more symptoms the better? Covid-19 vaccine side effects and long-term neutralizing antibody response
    E. Dutcher, E. Epel, Ashley E. Mason, Frederick M. Hecht, James E. Robinson, Stacy S. Drury, A. Prather · 2023 · medRxiv
  100. The role of vaccination route with an adenovirus-vectored vaccine in protection, viral control, and transmission in the SARS-CoV-2/K18-hACE2 mouse infection model
    Alexandria M. Dickson, Elizabeth Geerling, E. Taylor Stone, Mariah Hassert, Tara L. Steffen, Taneesh Makkena, Madeleine Smither, Katherine E. Schwetye, Jianfeng Zhang, Bertrand Georges et al. · 2023 · Frontiers in Immunology